Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.
The role of somatostatin analogues in the medical management of insulinomas is unclear. We describe an elderly patient with clinical and biochemical features of endogenous hyperinsulinism attributable to a benign islet B cell disorder whose incapacitating neuroglycopaenic symptoms responded dramatically to octreotide 50 micrograms subcutaneously at 2200 h each night. Octreotide suppressed inappropriate plasma concentrations of insulin thereby preventing fasting hypoglycaemia. Fasting concentrations of proinsulin, and 32-33 split proinsulin, as determined by two-site monoclonal antibody-based immunoradiometric assays, were also suppressed by octreotide.
Krentz
A J
AJ
Diabetic Clinic, General Hospital, Birmingham, UK.
Pace
J
J
Somerville
W
W
Clark
P M
PM
Nattrass
M
M
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy*; D007003:Hypoglycemia / Q000517:prevention & control; D007340:Insulinoma / Q000150:complications*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000150:complications*
D015282:Octreotide